DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Tatva Chintan Pharma Chem Limited — Credit Rating

NSE 1 hr ago·8 Sept 2026, 11:46 am

Tatva Chin Pharm Chem

Tatva Chintan Pharma Chem Limited has informed stock exchanges about an update regarding its credit rating. The company has disclosed that its credit rating has been revised or is under review by a rating agency.

This information is significant for investors as credit ratings provide an independent assessment of a company's ability to meet its financial obligations. A change in rating can influence the cost of borrowing and the company's access to capital markets, impacting its financial health and operational flexibility.

Investors should monitor the specific rating agency's report to understand the reasons behind the change. This will help in assessing the company's current financial position and future stability in the market.